Shire inks a $225M rare disease deal on the eve of life with AbbVie

Damian Garde

has signed a $ 225 million agreement to brighten its future in diseases, bolstering a major selling point for as the two prepare for a $ 54.7 billion merger.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS